New Zealand Formulary
Menu Close Menu

Fewer cancers.
Better survival.
Equity for all.

Systemic Anti-Cancer Therapy Regimen Library

Home > LEU ALL - UKALL14 [over 40 years] > LEU - UKALL14 [over 40 years] - Phase 1 Induction
This regimen is a component of LEU ALL - UKALL14 [over 40 years]

UKALL14 [over 40 years] - Phase 1 Induction (LEU ALL - UKALL14 [over 40 years])

Treatment Overview

Cycle 1 - 28 days

Cycle length:
28

Intrathecal metHOTREXATe:

  • As per regimen is for CNS prophylaxis; for CNS disease or traumatic lumbar puncture, escalation to a treatment strategy will be required.
  • Day of administration can be moved +/- 3 days.
  • For Ommaya reservoir reduce dose to 6 mg intraventricularly.

pegaspargase:

  • DO NOT use in BCR-ABL1+ (Philadelphia positive) patients.
  • There is limited data available for use of pegaspargase in patients 65 years and older. Strongly consider not using pegaspargase in patients 65 years and older.
  • Consideration can be given to reducing dose of pegaspargase to 500 international units/m2 for certain patients.
  • Monitor patients for one hour after administration of pegaspargase in a setting with resuscitation equipment and other agents necessary to treat anaphylaxis (e.g. adrenaline, oxygen, intravenous steroids, antihistamines).
  • See also Additional details for Further information on pegaspargase.

Cycle details

Cycle 1 - 28 days

Medication Dose Route Days Max Duration
DAUNOrubicin * 30 mg/m² intravenous 1, 8, 15,
22		 20 minutes
vinCRISTine 1.4 mg/m² Cap dose per administration at: 2 mg intravenous 1, 8, 15,
22		 10 minutes
dexamethasone 10 mg/m² Once daily Cap dose per administration at: 20 mg oral administration 1 to 4,
8 to 11,
15 to 18
metHOTREXATe 12 mg flat dosing intrathecal injection 14
paracetamol * 1000 mg flat dosing oral administration 18
loratadine * 10 mg oral administration 18
famotidine * 20 mg oral administration 18
pegaspargase * 1000 international unit/m² intravenous 18 120 minutes

Intrathecal metHOTREXATe:

  • As per regimen is for CNS prophylaxis; for CNS disease or traumatic lumbar puncture, escalation to a treatment strategy will be required.
  • Day of administration can be moved +/- 3 days.
  • For Ommaya reservoir reduce dose to 6 mg intraventricularly.

pegaspargase:

  • DO NOT use in BCR-ABL1+ (Philadelphia positive) patients.
  • There is limited data available for use of pegaspargase in patients 65 years and older. Strongly consider not using pegaspargase in patients 65 years and older.
  • Consideration can be given to reducing dose of pegaspargase to 500 international units/m2 for certain patients.
  • Monitor patients for one hour after administration of pegaspargase in a setting with resuscitation equipment and other agents necessary to treat anaphylaxis (e.g. adrenaline, oxygen, intravenous steroids, antihistamines).
  • See also Additional details for Further information on pegaspargase.

Full details

Cycle 1 - 28 days

Day: 1

Medication Dose Route Max duration Details
DAUNOrubicin * 30 mg/m² intravenous 20 minutes
Instructions:

Warning vesicant—ensure vein is patent prior to administration, administer vesicant as per institutional policy and monitor for signs of extravasation throughout administration.
vinCRISTine 1.4 mg/m² Cap dose per administration at: 2 mg intravenous 10 minutes
Instructions:
  • Diluted in a minibag.
  • FOR INTRAVENOUS USE ONLY – fatal if given by any other routes.
  • Warning vesicant—ensure vein is patent prior to administration, administer vesicant as per institutional policy and monitor for signs of extravasation throughout administration.
dexamethasone 10 mg/m² Once daily Cap dose per administration at: 20 mg oral administration
Instructions:

Take in the morning with food.

Day: 2

Medication Dose Route Max duration Details
dexamethasone 10 mg/m² Once daily Cap dose per administration at: 20 mg oral administration
Instructions:

Take in the morning with food.

Day: 3

Medication Dose Route Max duration Details
dexamethasone 10 mg/m² Once daily Cap dose per administration at: 20 mg oral administration
Instructions:

Take in the morning with food.

Day: 4

Medication Dose Route Max duration Details
dexamethasone 10 mg/m² Once daily Cap dose per administration at: 20 mg oral administration
Instructions:

Take in the morning with food.

Day: 8

Medication Dose Route Max duration Details
DAUNOrubicin * 30 mg/m² intravenous 20 minutes
Instructions:

Warning vesicant—ensure vein is patent prior to administration, administer vesicant as per institutional policy and monitor for signs of extravasation throughout administration.
vinCRISTine 1.4 mg/m² Cap dose per administration at: 2 mg intravenous 10 minutes
Instructions:
  • Diluted in a minibag.
  • FOR INTRAVENOUS USE ONLY – fatal if given by any other routes.
  • Warning vesicant—ensure vein is patent prior to administration, administer vesicant as per institutional policy and monitor for signs of extravasation throughout administration.
dexamethasone 10 mg/m² Once daily Cap dose per administration at: 20 mg oral administration
Instructions:

Take in the morning with food.

Day: 9

Medication Dose Route Max duration Details
dexamethasone 10 mg/m² Once daily Cap dose per administration at: 20 mg oral administration
Instructions:

Take in the morning with food.

Day: 10

Medication Dose Route Max duration Details
dexamethasone 10 mg/m² Once daily Cap dose per administration at: 20 mg oral administration
Instructions:

Take in the morning with food.

Day: 11

Medication Dose Route Max duration Details
dexamethasone 10 mg/m² Once daily Cap dose per administration at: 20 mg oral administration
Instructions:

Take in the morning with food.

Day: 14

Medication Dose Route Max duration Details
metHOTREXATe 12 mg flat dosing intrathecal injection
Instructions:
  • Day of administration can be moved +/- 3 days.
  • Adhere to local institution policy for intrathecal administration.
  • For Ommaya reservoir reduce dose to 6 mg intraventricularly.

Day: 15

Medication Dose Route Max duration Details
DAUNOrubicin * 30 mg/m² intravenous 20 minutes
Instructions:

Warning vesicant—ensure vein is patent prior to administration, administer vesicant as per institutional policy and monitor for signs of extravasation throughout administration.
vinCRISTine 1.4 mg/m² Cap dose per administration at: 2 mg intravenous 10 minutes
Instructions:
  • Diluted in a minibag.
  • FOR INTRAVENOUS USE ONLY – fatal if given by any other routes.
  • Warning vesicant—ensure vein is patent prior to administration, administer vesicant as per institutional policy and monitor for signs of extravasation throughout administration.
dexamethasone 10 mg/m² Once daily Cap dose per administration at: 20 mg oral administration
Instructions:

Take in the morning with food.

Day: 16

Medication Dose Route Max duration Details
dexamethasone 10 mg/m² Once daily Cap dose per administration at: 20 mg oral administration
Instructions:

Take in the morning with food.

Day: 17

Medication Dose Route Max duration Details
dexamethasone 10 mg/m² Once daily Cap dose per administration at: 20 mg oral administration
Instructions:

Take in the morning with food.

Day: 18

Medication Dose Route Max duration Details
dexamethasone 10 mg/m² Once daily Cap dose per administration at: 20 mg oral administration
Instructions:

Take in the morning with food.
paracetamol * 1000 mg flat dosing oral administration
Instructions:

30 minutes prior to pegaspargase.
loratadine * 10 mg oral administration
Instructions:

30 minutes prior to pegaspargase.
famotidine * 20 mg oral administration
Instructions:

30 minutes prior to pegaspargase.
pegaspargase * 1000 international unit/m² intravenous 120 minutes
Instructions:
  • DO NOT use in BCR-ABL1+ patients.
  • Strongly consider omitting in patients 65 years and older.
  • Consideration can be given to reducing dose of pegaspargase to 500 international units/m2 for certain patients.
  • Monitor patients for one hour after administration of pegaspargase in a setting with resuscitation equipment and other agents necessary to treat anaphylaxis (e.g. adrenaline, oxygen, intravenous steroids, antihistamines).
Additional details:

Day: 22

Medication Dose Route Max duration Details
DAUNOrubicin * 30 mg/m² intravenous 20 minutes
Instructions:

Warning vesicant—ensure vein is patent prior to administration, administer vesicant as per institutional policy and monitor for signs of extravasation throughout administration.
vinCRISTine 1.4 mg/m² Cap dose per administration at: 2 mg intravenous 10 minutes
Instructions:
  • Diluted in a minibag.
  • FOR INTRAVENOUS USE ONLY – fatal if given by any other routes.
  • Warning vesicant—ensure vein is patent prior to administration, administer vesicant as per institutional policy and monitor for signs of extravasation throughout administration.

Additional details

Section 1: Further information on pegaspargase

  • Pegaspargase (and asparaginase products) should only be administered by centres with appropriate expertise. 
  • There is limited data available for use of pegaspargase in patients 65 years and older. Strongly consider not using pegaspargase in patients 65 years and older.
  • Consideration can be given to reducing dose of pegaspargase to 500 international units/m2 for certain patients. 
  • Prior to using pegaspargase perform a baseline abdominal ultrasound scan is recommended to examine the biliary tract, pancreas and hepatic echotexture. Pegasparagase is contraindicated in those with a history of severe significant hepatic impairment, including alcoholic liver disease, autoimmune or viral hepatitis, and steatohepatitis/NASH.
  • If after pegaspargase there is any evidence of steatosis/liver disease, perform an ultrasound of the liver. 
  • Development of anti-asparaginase antibodies may be associated with low asparaginase activity levels. As a precaution, periodic measurement of the asparaginase activity level in serum or plasma is recommended. 
  • Routine monitoring for bone marrow suppression, coagulations abnormalities, pancreatitis, hepatic toxicity, hyperuricaemia, hyperglycaemia, ketoacidosis and hypertriglyceridaemia is required. See Additional information - pegaspargase.
  • To reduce risk of hypersensitivity to pegaspargase avoid using other pegylated products e.g. pegFILGRASTIM if there is a suitable non-pegylated form.

Supportive Care Factors

Factor Value
Antifungal prophylaxis: Routine antifungal prophylaxis recommended
Antiviral prophylaxis for herpes virus: Routine antiviral prophylaxis recommended
Constipation risk: Consider prescribing laxatives with this treatment
Emetogenicity: Variable
Gastroprotection: Gastroprotection is recommended
Hypersensitivity / Infusion related reaction risk: High - routine premedication recommended
Pneumocystis jirovecii pneumonia (PJP) prophylaxis: Routine antibiotic prophylaxis recommended
Tumour lysis syndrome prophylaxis: Tumour lysis syndrome prophylaxis is recommended

Antifungal prophylaxis: Inhibition of CYP3A4 by azole antifungals may lead to reduced vinCRISTine clearance and increased toxicities. Strategies to avoid this interaction may include a washout period after azole administration or using a non-azole antifungal for prophylaxis.


Antiviral prophylaxis for hepatitis B virus: Guidance is limited to high-risk anti-cancer medicines. Clinicians will need to assess individual patient risk for other anti-cancer medicines.


Emetogenicity: MEDIUM days 1, 8, 15 and 22; MINIMAL day 18.


Gastroprotection: Gastroprotection agents are only intended for short term use while patient is receiving corticosteroid treatment doses.

References

No references

* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.

s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.